tradingkey.logo

Sol Gel Technologies Ltd

SLGL
41.580USD
-0.580-1.38%
交易中 美东报价延迟15分钟
115.83M总市值
亏损市盈率 TTM

Sol Gel Technologies Ltd

41.580
-0.580-1.38%

关于 Sol Gel Technologies Ltd 公司

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd简介

公司代码SLGL
公司名称Sol Gel Technologies Ltd
上市日期Feb 01, 2018
CEO- -
员工数量34
证券类型Ordinary Share
年结日Feb 01
公司地址Golda Meir 7
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编- -
电话97289313433
网址http://www.sol-gel.com
公司代码SLGL
上市日期Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
其他
3.99%
持股股东
持股股东
占比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
其他
3.99%
股东类型
持股股东
占比
Corporation
64.86%
Hedge Fund
13.77%
Investment Advisor
7.86%
Individual Investor
5.14%
Insurance Company
4.68%
Research Firm
0.16%
其他
3.53%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
139.39K
5%
+139.39K
--
Aug 22, 2025
Phoenix Investment and Finances Ltd
247.02K
8.87%
+1.00
+0.00%
Jun 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
5.33K
0.19%
-3.90K
-42.24%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
-200.00
-38.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
308.00
0.01%
-1.00
-0.32%
Jun 30, 2025
SBI Securities Co., Ltd.
100.00
0%
--
--
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
May 01, 2025
Merger
10→1
公告日期
类型
比率
May 01, 2025
Merger
10→1

常见问题

Sol Gel Technologies Ltd的前五大股东是谁?

Sol Gel Technologies Ltd 的前五大股东如下:
M.Arkin Dermatology, Ltd.持有股份:1.81M,占总股份比例:64.86%。
Opaleye Management Inc.持有股份:139.39K,占总股份比例:5.00%。
Phoenix Investment and Finances Ltd持有股份:247.02K,占总股份比例:8.87%。
Arkin (Moshe)持有股份:143.26K,占总股份比例:5.14%。
Migdal Insurance and Financial Holdings Ltd持有股份:122.75K,占总股份比例:4.41%。

Sol Gel Technologies Ltd的前三大股东类型是什么?

Sol Gel Technologies Ltd 的前三大股东类型分别是:
M.Arkin Dermatology, Ltd.
Opaleye Management Inc.
Phoenix Investment and Finances Ltd

有多少机构持有Sol Gel Technologies Ltd(SLGL)的股份?

截至2025Q3,共有35家机构持有Sol Gel Technologies Ltd的股份,合计持有的股份价值约为286.02K,占公司总股份的10.27%。与2025Q2相比,机构持股有所增加,增幅为-79.61%。

哪个业务部门对Sol Gel Technologies Ltd的收入贡献最大?

在--,--业务部门对Sol Gel Technologies Ltd的收入贡献最大,创收--,占总收入的--%。
KeyAI